Q-omics provides the consensus-scored PDE4DIPP4 profile across patient tissues and cancer cell-line models. PDE4DIPP4 expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, PDE4DIPP4 is differentially expressed in 6, with the highest sampling consensus in KIRC. Additionally, PDE4DIPP4 RNA expression shows 10,595 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight HNSC, KIRC, and UVM as cancer lineages where PDE4DIPP4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PDE4DIPP4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PDE4DIPP4 survival associations across molecular data types. PDE4DIPP4 RNA expression shows survival associations in the most cancer types (13). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PDE4DIPP4 RNA expression–survival associations across cancer types. High PDE4DIPP4 expression shows unfavorable associations in COAD, ACC, MESO, UCEC and LUAD, but favorable associations in HNSC. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for PDE4DIPP4 RNA expression.
This table summarizes PDE4DIPP4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for PDE4DIPP4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PDE4DIPP4 shows lower tumor expression in ESCA, PRAD, THCA and LIHC and higher tumor expression in KIRC and BRCA. The KIRC box plot shows higher PDE4DIPP4 RNA expression in tumor versus normal tissue (log2 FC = +0.138, t-test p = .003).
This table shows molecular features associated with PDE4DIPP4 in patient tissues and cancer cell lines. In patient samples, PDE4DIPP4 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
